Biohaven Pharmaceutical has concluded patient enrolment in a Phase II/III clinical trial of vazegepant being developed for the treatment of migraine.

Based on the company’s Nojection Migraine platform, vazegepant is an antagonist of calcitonin gene-related peptide (CGRP) receptor. The drug has been formulated for intranasal administration.

The intranasal administration is made possible by Aptar Pharma’s Unidose System (UDS) intended for systemic drug delivery.

UDS holds US Food and Drug Administration (FDA) approval and does not require injection or a healthcare professional to administer.

The double-blind, randomised, placebo-controlled, dose-ranging Phase II/III trial is being conducted to assess the efficacy of the drug at 5mg, 10mg and 20mg doses, compared to placebo.

A total of more than 2,100 patients have been recruited for the study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vazegepant’s efficacy will be measured as freedom from pain and the most bothersome migraine-related symptom two hours after dosing.

The trial will also evaluate additional clinical measures, including pain relief and the return to normal functioning.

Biohaven Pharmaceutical CMO Elyse Stock said: “Our Phase II/III trial of vazegepant represents the first late-stage study of an intranasally delivered CGRP receptor antagonist, propelling us a step closer to providing patients with multiple, easy-to-use formulations to treat migraine.

“Vazegepant is complementary to our lead migraine asset, rimegepant, which has met the primary efficacy endpoints in three completed Phase III clinical trials and is currently under review with the FDA.”

Apart from vazegepant and rimegepant, the company’s portfolio of CGRP receptor antagonists includes multiple other candidates for the acute preventive treatment of migraine.

Last month, Biohaven completed enrolment of more than 1,600 patients in a Phase III trial of rimegepant.